Core Viewpoint - The company has established itself as a significant strategic supplier in the agricultural protection industry, ranking among the top five companies [1] Group 1: Strategic Partnerships - The company has successfully become a strategic supplier for several international pharmaceutical giants and has partnered with many of the top 20 pharmaceutical companies [1] - This recognition has provided the company with a competitive product advantage and broad market opportunities [1] Group 2: Business Segments - The company's functional chemicals division primarily focuses on self-produced and self-sold products [1] - Key areas covered by this division include personal care and battery sectors [1]

Core Viewpoint - Lianhua Technology's stock price has experienced significant fluctuations, with a year-to-date increase of 90.53% but a recent decline in the last five trading days by 6.52% [2] Company Overview - Lianhua Technology, established on September 14, 1998, and listed on June 19, 2008, is located in Taizhou, Zhejiang Province. The company operates in three main sectors: pesticides, pharmaceuticals, and functional chemicals [2] - The revenue composition of Lianhua Technology is as follows: pesticides 54.03%, pharmaceuticals 32.32%, functional chemicals 8.42%, equipment and engineering services 4.88%, and others 0.36% [2] Financial Performance - For the first half of 2025, Lianhua Technology reported revenue of 3.15 billion yuan, a year-on-year increase of 5.76%, and a net profit attributable to shareholders of 224 million yuan, reflecting a substantial growth of 1481.94% [3] - The company has distributed a total of 960 million yuan in dividends since its A-share listing, with 129 million yuan distributed over the past three years [4] Shareholder Information - As of June 30, 2025, Lianhua Technology had 72,300 shareholders, an increase of 88.92% from the previous period, with an average of 12,533 circulating shares per shareholder, a decrease of 47.07% [3] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 40.36 million shares, which is an increase of 21.34 million shares from the previous period [4] Market Activity - On September 23, Lianhua Technology's stock price fell by 2.06%, trading at 10.46 yuan per share, with a total transaction volume of 67.35 million yuan and a turnover rate of 0.70% [1] - The stock has appeared on the "Dragon and Tiger List" nine times this year, with the most recent appearance on June 25, where it recorded a net buy of -46.85 million yuan [2]

Core Insights - The company has a planned production capacity of 20,000 tons/year for lithium hexafluorophosphate and 10,000 tons/year for lithium bis(fluorosulfonyl)imide, but production is limited due to market conditions [2] - The company does not produce PVDF-HFP water-based adhesives or sulfide electrolyte materials [2] - The company has formed strategic partnerships with leading domestic and international manufacturers to provide differentiated and customized product services, leveraging its technical expertise and production resources [2]

Group 1 - The company, Linghua Technology (002250.SZ), confirmed on September 22 that it does not have any business related to photoresist [1]

Group 1 - The company has planned an annual production capacity of 20,000 tons for lithium hexafluorophosphate (LiPF₆) and 10,000 tons for lithium bis(fluorosulfonyl)imide (LiFSI) [1] - Due to market conditions, the actual output of these products is limited [1] - The company does not currently produce PVDF-HFP water-based adhesives or sulfide electrolyte materials [1] Group 2 - The company has formed strategic partnerships with leading domestic and international manufacturers [1] - It leverages its technical expertise and production resources to provide differentiated and customized product services [1] - The company aims to develop and offer various competitive key chemicals in collaboration with its customers [1]

Core Points - On September 16, 2025, the company will hold a staff representative meeting in its conference room [2] - The staff representatives unanimously agreed to elect Mr. Fan Xiaobin as the employee representative director of the company's ninth board of directors [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index in the next six months [4]. Core Viewpoints - The company's performance in the first half of 2025 exceeded market expectations, showing signs of recovery with a revenue increase of 5.76% year-on-year and a significant net profit growth of 1481.94% [1][2]. - The recovery in profitability from the agricultural protection business and significant growth in the pharmaceutical sector are key drivers of the company's improving performance [2][8]. - The company is focusing on expanding its overseas operations and enhancing its product offerings in the agricultural protection and pharmaceutical sectors, which are expected to contribute to long-term growth [8][9]. Financial Summary - **Revenue Forecast**: The company is projected to achieve revenues of 68.82 billion, 79.49 billion, and 90.29 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 21.2%, 15.5%, and 13.6% [9]. - **Net Profit Forecast**: Expected net profits are 4.09 billion, 5.81 billion, and 7.28 billion yuan for the same years, with growth rates of 297.0%, 42.0%, and 25.2% [9]. - **Earnings Per Share (EPS)**: The projected EPS for 2025, 2026, and 2027 are 0.44, 0.63, and 0.79 yuan, respectively [9]. - **Valuation Ratios**: The price-to-earnings (P/E) ratios are expected to be 25.6, 18.0, and 14.4 for the years 2025, 2026, and 2027 [9]. Business Segment Performance - **Agricultural Protection**: Revenue from agricultural intermediates was 17.02 billion yuan, with a year-on-year decline of 9.13%. However, the gross margin improved to 24.99%, up 9.48 percentage points year-on-year [2]. - **Pharmaceuticals**: The pharmaceutical segment saw revenue of 10.18 billion yuan, a year-on-year increase of 42.80%, with a stable gross margin [8]. - **New Energy**: The company has commercialized four new energy products and is advancing several others through various stages of development, indicating potential for a second growth curve [9].

Group 1 - The company, Lianhua Technology, announced the convening of its 9th First Board Meeting on September 16, 2025, to discuss the election of a director for company affairs [1] - For the first half of 2025, Lianhua Technology's revenue composition was 99.64% from industrial operations and 0.36% from other businesses [1] - As of the report date, Lianhua Technology's market capitalization was 10.2 billion yuan [1]

特此公告。 联化科技股份有限公司董事会 二〇二五年九月十七日 证券代码：002250 证券简称：联化科技 公告编号：2025-041 联化科技股份有限公司 关于选举第九届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《联化科技股份有限公司章程》（以下简称"《公司章 程》"）等有关规定，公司于2025年9月16日在公司会议室召开职工代表大会。经 与会职工代表认真审议，一致同意选举樊小彬先生为公司第九届董事会职工代表 董事，任期自本次职工代表大会选举通过之日起至公司第九届董事会届满之日止。 樊小彬先生简历附后。 樊小彬先生符合《公司法》《公司章程》等法律法规和制度规定的董事任职 资格及条件。公司第九届董事会中兼任公司高级管理人员以及由职工代表担任的 董事人数总计不超过公司董事总数的二分之一。 附件： 樊小彬简历 樊小彬先生，中国国籍，1976年3月出生，硕士。历任联化科技监事、研发 中心副主任、农药与精细化学品研发部主任、总裁助理。兼任江苏 ...

证券代码：002250 证券简称：联化科技 公告编号：2025-040 联化科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议时间：2025年9月16日（星期二）15时00分 2、会议地点：浙江省台州市黄岩区江口经济开发区永椒路8号会议室 3、会议召集人：联化科技股份有限公司董事会 公司董事、监事、高级管理人员和见证律师出席或列席了会议，符合《公司法》 和《公司章程》的有关规定。 二、议案审议表决情况 本次股东大会按照会议议程，以现场记名投票与网络投票表决方式审议通过了 如下决议： 1、审议通过《关于修订<公司章程>及相关议事规则的议案》，该项议案获得出 席本次股东大会有效表决权股份总数的 2/3 以上通过。 表决结果： 4、会议方式：现场投票与网络投票相结合的方式 5、现场会议主持人：董事长王萍女士 6、会议的召集、召开与表决程序符合《公司法》《上市公 ...